This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Company Statement: IMS Health clarifies its market study regarding countries of origin for drugs

( September 13, 2011, 16:32 GMT | Official Statement) -- MLex Summary: IMS Health has provided the German Cartel Office, the Bundeskartellamt, with information in relation to its market study on countries of origin, which has come under criticism in the past weeks. The study offers an overview of the countries of origin for selected pharmaceutical products, supports customers in areas such as product planning and logistics, and helps ensure the supply of drugs, the company says....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections